CalciMedica develops drug candidates that block CRAC channels to treat serious inflammatory and immune conditions. CALC reports earnings on Wed, Nov 11, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 20 | Guggenheim | Initiated | Buy |
Seasonality
How CALC has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2023.
Whale Options Flow
90DNo whale options trades in CALC in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CALC is in one of them and how their past CALC trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered CALC in an article yet. Here's the latest on the wider market.
About CalciMedica
CalciMedica is a biopharmaceutical company based in La Jolla, California, that develops drug candidates for serious illnesses involving inflammation and damage to tissue cells. Its drugs work by blocking CRAC channels, which play a role in immune and inflammatory signaling. Its lead candidate, Auxora, is an intravenous treatment that has been studied in acute care settings such as acute pancreatitis and kidney injury. The company is also researching the approach for other conditions, including pulmonary arterial hypertension. Its products are still in development and are not yet approved for sale, and they are intended for hospital and specialist use.
- Headquarters
- La Jolla, CA